Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Metastatic Neuroendocrine Prostate Cancer 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × copper dotatate CU-64 × 1 year × Clear all
NCT06379217 2026-06-10

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡